Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:24 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
NCT05221320 · BioMed Valley Discoveries, Inc · PHASE2 · terminated · last registry update 2025-09-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of Enrollment for Remaining Open Baskets” | – | Registry record, BioMed Valley Discoveries, Inc |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MAPK3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-07-27Also stopped (terminated): Dana-Farber Cancer Institute, BVD-523 (NCT03417739)
- 2026-04-14Results posted on the registry: National Cancer Institute (NCI), Ensartinib + Erdafitinib (NCT03155620)
- 2024-11-21Results posted on the registry: Merck Sharp & Dohme LLC, MK-8353 + Pembrolizumab (NCT02972034)
- 2024-11-21Also stopped (terminated): Merck Sharp & Dohme LLC, MK-8353 + Pembrolizumab (NCT02972034)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision